Reginald Swift, founder and CEO of Rubix LS, uses innovation at a grander scale to change how health outcomes can be realized through patient product and service innovation
It works for women and men
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, distinguishing it from currently approved weight management agents
Polymorphic variations in manganese superoxide dismutase (MnSOD), glutathione peroxidase-1 (GPX1), and catalase (CAT) contribute to elevated plasma triglyceride levels in Chinese patients with type 2 diabetes or diabetic cardiovascular disease
Conclusions Treatment with semaglutide, compared to placebo, is associated with significant lower incidence of all-cause and CV mortality, as well major CV and kidney events across the continuum of cardio-kidney-metabolic syndrome
Loss of muscle mass may occur on GLP-1s